Yahoo Finance / Simply Wall Street article on if $LENZ Therapeutics has enough cash runway for their expansion into the market staring in Q4

https://finance.yahoo.com/news/companies-lenz-therapeutics-nasdaq-lenz-112517218.html

TLDR; $LENZ Therapeutics article on how the cash runway looks for them as they begin scaling and distributing their eye drop VIZZ into the market starting October.

Spoiler: they have 4.4 years of adoption rate is horrible, they will reach break even quickly even with very modest adoption rate of the eye drops. Biggest risk now is if the public rejects the drops due to either its price point $80/month or its side effects are worse than the blind studies relieved.